Enliven Therapeutics’ Strong Q3 Results and Cash Runway Support Buy Rating; Price Target Unchanged at $73
at www.tipranks.com (Fri, 13-Nov 9:37 AM)
ELVN Gains a Clear FDA Path for a 450-Patient Phase 3 Relcobatinib Study in Previously Treated CML
Market Chameleon (Wed, 7-Oct 11:04 AM)